Cite
HARVARD Citation
Hurvitz, S. et al. (n.d.). Patient-reported outcomes (PROs) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician's choice chemotherapy treatment (PCT): a focus on the EMBRACA HR+/HER2- subpopulation. Breast. pp. S27-S28. [Online].